<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077462</url>
  </required_header>
  <id_info>
    <org_study_id>21HT10602</org_study_id>
    <nct_id>NCT05077462</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers</brief_title>
  <official_title>An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of AJU-C52H Compared to Coadministration of C52R1M With C52R2 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AJU Pharm Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AJU Pharm Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetic characteristics of AJU-C52H in healthy adults&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to assess the safety and pharmacokinetic characteristics between&#xD;
      co-administration of C52R1M with C52R2 and administration of AJU-C52H.&#xD;
&#xD;
      This is an open-label, randomized, single-dose, 2x2 crossover study in healthy subjects to&#xD;
      assess the bioequivalence after taking the study drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of AJU-C52</measure>
    <time_frame>Pre-dose (0 hour), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>AUCt: Area under the concentration-time curve from time zero to time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of AJU-C52</measure>
    <time_frame>Pre-dose (0 hour), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>Cmax: Maximum plasma concentration of the drug</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C52R1M Tab. and C52R2 Tab.</intervention_name>
    <description>Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <other_name>Reference Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AJU-C52H</intervention_name>
    <description>Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <other_name>Test Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers aged ≥ 19-year-old&#xD;
&#xD;
          2. Weight ≥ 50kg (man) or 45kg (woman), with calculated body mass index(BMI) of 18 to 30&#xD;
             kg/m2&#xD;
&#xD;
          3. Those who are eligible for adequate blood pressure criteria during screening tests&#xD;
             Systolic blood pressure: 90 to 139 mmHg Diastolic blood pressure: 60 to 89 mmHg&#xD;
&#xD;
          4. Those who have no congenital chronic disease or chronic disease requiring treatment&#xD;
             and who have no pathological symptoms or findings&#xD;
&#xD;
          5. Those who are eligible for clinical trials based on laboratory (hematology, blood&#xD;
             chemistry, serum, urine test) and 12-lead ECG results during screening tests&#xD;
&#xD;
          6. Those who agree to contraception during the participation of clinical trial&#xD;
&#xD;
          7. Those who voluntarily decide to participate and agree to comply with the cautions&#xD;
             after hearing and fully understanding the detailed description of this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who received investigational product or bioequivalence test drug within 6 months&#xD;
             before the first administration of clinical trial drug&#xD;
&#xD;
          2. Those who take barbiturate and related (causing induction or inhibition of metabolism)&#xD;
             drug within 1 month before the first administration of clinical trial drug&#xD;
&#xD;
          3. Those who donated whole blood and apheresis within 8 weeks or received transfusion&#xD;
             within 4 weeks&#xD;
&#xD;
          4. Those who has a history of gastrointestinal surgery&#xD;
&#xD;
          5. Those who exceeding an alcohol and smoke consumption criteria Alcohol: Men - 21&#xD;
             glass/week, Women - 14 glass/week (1 glass: Soju 50 mL, Beer 250mL, Wine 30 mL) Smoke:&#xD;
             20 cigarettes/day&#xD;
&#xD;
          6. Those who has a disease history of diabetic mellitus, nephropathy, biliary&#xD;
             obstruction, dihydropyridine sensitivity, angioedema&#xD;
&#xD;
          7. Genetic problems such as galactose intolerance, Lapp lactose deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
          8. Those who are deemed unfit by the investigators to participate in the clinical trial&#xD;
             for other reasons including the results of laboratory tests&#xD;
&#xD;
          9. Women who are pregnant or who may be pregnant and breastfeed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jaewoo Kim, M.D., Ph.D.</last_name>
    <phone>+82-70-4665-9193</phone>
    <email>m3116@newyjh.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H+ Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Republic Of South Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaewoo Kim</last_name>
      <phone>+827046659193</phone>
      <email>m3116@newyjh.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryptophycin 52</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

